JingTai Holdings Secures Nearly $6 Billion AI Drug Discovery Deal, Signaling Massive Capital Inflow into AI Pharma

Large Orders Surge in AI Pharmaceutical Field. On the 5th, XtalPi Holdings Limited made a significant announcement: XtalPi completed the signing of a pipeline cooperation agreement with DoveTree, with a total order value nearing 6 billion US dollars. In response to this major deal, the capital market reacted positively. On the 6th, XtalPi Holdings Limited opened with a significant increase, and by the closing, the rise exceeded 12%.

 

 

On August 5, XtalPi Holdings Limited announced that its indirectly wholly-owned subsidiary, Shenzhen XtalPi Technology Co., Ltd., had completed the signing of a pipeline cooperation agreement with DoveTree, with a total order value of nearly USD 6 billion.

 

According to the agreement, the group will utilize its end-to-end AI drug discovery platform based on "AI + robotics" to target multiple selections by DoveTree.TumorStudy, Immunity and InflammationDisease, targets in the fields of neurological diseases and metabolic disorders, discovering and developing small molecule and antibody candidate drugs. DoveTree will obtain the exclusive global development and commercialization rights for the above products.

 

The announcement states that the group has received the first payment of 51 million US dollars as agreed in the agreement. Subject to the terms of the final agreement, it is entitled to receive a further payment of 49 million US dollars and is eligible for potential regulatory and commercial milestone payments amounting to 5.89 billion US dollars, as well as potential royalties in the single-digit percentage based on the product's annual net sales.

 

XtalPi is an innovative platform technology company based on quantum physics, empowered by artificial intelligence, and driven by robotics. It is one of the "Four Little Dragons of AI Pharmaceutical Industry" along with Deep Intelligent Pharma, Insilico Medicine, and Metis Technology.

 

CN Health noticed that the total amount of this super large order is equivalent to more than 100 times the revenue of XtalPi Holdings Limited in 2024.

 

According to media reports, this order represents the largest single collaboration in the global AI drug discovery field to date, as well as a significant milestone for China's biotechnology industry.PharmaceuticalsOne of the top-ranking License-out deals in history.

 

 

Drug development typically takes more than a decade and requires an investment of $1 billion to $1.5 billion, but the success rate is very low. The emergence of AI technology is attempting to break this curse. In recent years, the market size of AI pharmaceuticals has also rapidly expanded.

 

Research data shows that from 2019 to 2024, the market size of China's AI pharmaceuticals industry grew from 0.7 billion yuan to 7.3 billion yuan, with an annual compound growth rate of 47.8%. It is estimated that from 2025 to 2028, the market size will increase from 12.1 billion yuan to 58.6 billion yuan, with an annual compound growth rate of 68.3%.

 

In the past two months, the "AI Pharmaceutical Four小龙" have also frequently传来 good news.

 

In June, the Phase IIa clinical trial results of Insilico Medicine's investigational drug Rentosertib (ISM001-055) were published in the prestigious academic journal *Nature Medicine*. Reportedly, Rentosertib is a potential first-in-class candidate drug for treating idiopathic pulmonary fibrosis, with its target identification and molecular design driven by the generative AI platform Pharma.AI.

 

At the beginning of this month, XtalPi's OpenCGT platform was launched in Daxing, Beijing. Lai Caida, co-founder and CEO of XtalPi, accepted an interview with China News Service.HealthDuring the interview, it was commented that the development of China's innovative drugs will usher in the stage of engineer dividend.

 

From the perspective of the entire industry, large orders in the AI pharmaceuticals field have been frequent recently. Novo Nordisk reached an $812 million collaboration with AI pharmaceutical company Deep Apple Therapeutics; Eli Lilly signed an agreement exceeding $650 million with Juvena Therapeutics (a U.S.-based AI pharmaceutical company); AstraZeneca formed a collaboration worth up to $5.3 billion with Shijie Group, utilizing Shijie Group's AI drug discovery platform to develop small molecule drug candidates... A massive influx of funds is flowing into the AI pharmaceuticals sector.

 

Regarding XtalPi's recent signing of a major contract, industry analysts noted that if the R&D pipeline proceeds smoothly to the commercialization stage, XtalPi Holdings Limited is expected to transform from a technology service provider to an innovative drug revenue-sharing participant. This will also validate the AI-driven pharmaceutical technology’s ability to complete the commercialization loop from "laboratory" to "market."